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Abstract
Objective—Approximately 40,000 incident cancer cases are reported in VA Central Cancer
Registry (VACCR) annually (~3% of United States cancer cases). Our objective was to provide
the first comprehensive description of cancer incidence as reported in VACCR.
Methods—Data were obtained from VACCR for incident cancers diagnosed in VA. Analyses
focused on 2007 data. Cancer incidence among VA patients was compared to the general U.S.
cancer population.
Results—In 2007, 97.5% of VA cancers were diagnosed among men. Approximately 78.5% of
newly diagnosed patients were White, 19.0% Black, and 2.5% were another race. Median age at
diagnosis was 66 years. The geographic distribution of cancer patients in VA aligns that of VA
users. The most commonly diagnosed cancers were similar between VA and the U.S. male cancer
population. The five most frequently diagnosed cancers among VA cancer patients were: prostate
(31.8%), lung/bronchus (18.8%), colon/rectum (8.6%), urinary bladder (3.6%), and skin
melanomas (3.4%). VA patients were diagnosed at an earlier stage of disease for the three most
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commonly diagnosed cancers – lung/bronchus, colon/rectum, and prostate – compared to the U.S.
male cancer population.
Conclusions—Registry data indicate that incident cancers in VA in 2007 approximately
mirrored those observed among U.S. men.
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INTRODUCTION
In 2007, approximately five million Veterans received care in the Veterans Affairs (VA)
healthcare system, making it one of the leading U.S. providers of healthcare.1, 2 Moreover,
approximately 3% of U.S. cancer diagnoses are made in VA annually. This equates to
~40,000 incidence cancer cases reported in the VA Central Cancer Registry (VACCR) each
year. While state and national cancer statistics are routinely reported3, 4, there has been no
public reporting of cancer incidence from the VACCR. The objective of this paper is to
provide the first-ever comprehensive description of cancer incidence as reported in the
VACCR in 2007. To achieve this objective we present cancer frequencies within the VA
population in 2007 and provide comparisons with the larger U.S. cancer population based on
incidence estimates developed annually by the American Cancer Society.4
The VA patient population is unique. In order to qualify to receive VA healthcare, patients
must have served in the United States armed forces. VA users must undergo a financial
needs assessment and may receive care at a reduced cost due to financial need or because of
a service-related injury or disease.5 As a result of this qualification process, users of VA
healthcare are more likely to have poor health status, have lower levels of education and
income, and be of minority race.6
To provide health care for this distinct patient population, the VA currently operates a
network of approximately 153 hospital facilities (at least one in each state, the District of
Columbia, and Puerto Rico), and 788 community-based outpatient clinics focusing on
primary care.7 Approximately 143 VA hospitals have cancer diagnostic and treating
capabilities. These facilities share a national electronic health record (EHR) system.8 This
EHR provides the basic information to equip registry activities. One hundred thirty-two VA
facilities have some level of cancer registry activity. There are full cancer registry programs
at 129 hospitals, covering the spectrum of the VA system. The VA Central Cancer Registry
has maintained a comprehensive database containing records of cancer cases treated in the
VA system retrospectively to 1995. We report VACCR cancer incidence information from
2007, which is the most current, complete year of data.
METHODS
The analyses for this report were conducted as part of a VA data quality improvement
project approved by the Chief Officer of Patient Care Services. The goal of the project was
to provide a descriptive analysis of cancer incidence in the VA.
The VA Central Cancer Registry
In response to a national directive in 1998, many VA facilities began local cancer registry
operations. Additional VA facilities became operational until all facilities were accruing
data in 2001 (Table 1). The VACCR was formally recognized in 2003.9 After reaching
national participation, the number of new cases reported through the VA registry system has
remained stable at approximately 40,000 new cases annually.
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The VACCR retrospectively abstracted incident cases diagnosed on or after January 1, 1995.
VACCR continues to abstract prospectively, striving to capture all cancer cases occurring
within the VA system. It has been estimated that VACCR captures nearly 90% of cancer
cases treated in VA.9,10 To achieve this level of case identification and abstraction, cancer
registrars in VA use custom software, called OncoTraX, which is directly integrated with the
VA electronic health record system. Cancer registrars manually abstract case data,
conforming to standards set by the North American Association of Central Cancer Registries
(NAACCR). In keeping with the NAACCR criteria for reportable cases, the VACCR
includes cases that are diagnosed outside of the VA healthcare system if they subsequently
receive care within VA. Data are then aggregated into the national cancer registry located in
Washington, DC. Once the data are centralized, cases are merged and quality assurance
checks are conducted. Data in the registry are retrospectively updated as new information is
obtained by VACCR.
All VA medical centers diagnosing and treating veterans with reportable malignancies are
required to collect and submit patient-level data to the VACCR biannually. To ensure data
integrity, local registry data files must meet the NAACCR electronic quality standards
before being consolidated into the national master file.11 As a result of this process, VACCR
incurs reporting delays slightly in excess of one year. By comparison, other national cancer
registries generally lag by two years post-diagnosis.12
For this analysis, data were obtained from VACCR for all incident cases diagnosed in the
Veteran Affairs population from 1995 through 2007, the most current year that has been
internally validated.
This report describes cancer incidence using VACCR data from 2007. In situ cancers
(n=3,684) were excluded from analysis unless otherwise noted; these were identified by a
Surveillance, Epidemiology and End Results (SEER) summary stage of 0. SEER is a
constellation of geographically-based cancer registries that collect information on incidence,
prevalence, and survival from approximately one-fourth of the nation. This exclusion
primarily affected the reported frequency of urinary bladder cancer (n=1,252) and melanoma
of the skin (n=1,178). No other exclusions were made.
Descriptive Variables
Within the VA, geographic location is described by Veterans Integrated Service Networks
(VISN). To simplify analysis, each case’s VISN of origin was sub-grouped into geographic
regions. These regions were defined as follows: 1) Northeastern region, defined as VISNs 1,
2, 3, and 4; 2) Southern region, defined as VISNs 5, 6, 7, 8, 9, 16, and 17; 3) Midwestern
region, defined as VISNs 10, 11, 12, and 15; and 4) Western region, defined as VISNs 18,
19, 20, 21, and 22. Due to VHA reorganization, VISNs 13 and 14 were merged to create
VISN 22. The regions described here are not equally distributed based on landmass or
patient population, but approximate standard geographical divisions of the U.S.13
Primary anatomic site was defined according to International Classification of Diseases for
Oncology (ICD-O-3) site and histology (i.e. type) codes.14 ICD-O-3 codes are commonly
used in pathology reports and cancer registries to capture information about the topography
and morphology of neoplasms. The unit of analysis throughout this report is the specific
cancer diagnosis and not unique patient. Therefore, patients with multiple cancer diagnoses
have multiple records in the database and may be included in the analysis several times. A
recurrence of an existing cancer diagnosis would not be coded separately.
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Frequency distributions of incident cancer diagnoses were evaluated by primary anatomical
site, sex, race, and geographic region. Cancer frequency trends within the VA population
were examined descriptively and comparisons were made with the larger U.S. cancer
population. Due to the categorical nature of these data, the characteristics of cancer cases
were summarized using frequencies and proportions. These were compared by sex and race
at the organ system level using a chi-square test when a minimum of 25 cases occurred in
each comparison group. Standard methods of age-adjustment to the 2000 projected U.S.
population15 were used in support of comparisons with the general U.S. population, as
follows: 1) within each age category, calculated the crude cancer incidence within the VA
based on the 2007 VA population; 2) within each age category, calculated the expected
cancer frequency for the 2000 Standard Population as (crude incidence in VA) x (2000
Standard Population); 3) summed the expected cancer frequencies over age categories; and
4) estimated the age-adjusted cancer incidence by dividing the summed frequencies by the
2000 Standard Population total. Statistical analyses were performed using Stata 10
(StataCorp LP, College Station, TX) and SAS 9.2 (SAS Institute Inc., Cary, NC).
RESULTS
Mirroring the format of other reports on cancer incidence in the United States, we have
provided a summary of key characteristics of patients with incident cancer among VA
patients.4 In addition to descriptive text and tables, we provide a brief interpretation of our
findings, which are categorized by: 1) overall incidence, 2) sex, 3) race, 4) age, 5)
geographic distribution, 6) stage at diagnosis, 7) and change in number of incident cases.
Demographic Characteristics
In fiscal year 2007 (October 1, 2006 through September 30, 2007), approximately five
million patients received care in VA.1 Approximately 39,505 of these patients were
diagnosed with cancer. Among these cancer diagnoses, 97.5% occurred in men
(38,513/39,505), while 2.5% were in women (989/39,505). To mitigate the potential impact
of outlying patients who were diagnosed at very young or very old ages, the median age at
diagnosis was examined rather than the mathematical mean. The median age of VA patients
newly diagnosed with cancer in 2007 was 66 years (min.=15, max.=100 years).
Approximately 78.5% of cancer occurred among White patients (31,010/39,505), compared
to approximately 19% among Black patients (7,523/39,505).
Incidence of Common Cancers
The number of incident cancer cases by anatomic site is described in Table 2. Within the
VA, these cancers are prostate, lung and bronchus, colon and rectum, urinary bladder,
melanomas of the skin, kidney, liver, non-Hodgkin’s lymphoma, leukemia, and larynx
(Table 2).
Sex Differences in Incidence
The most frequently diagnosed cancer among Veteran men was prostate cancer, accounting
for about 33% (12,543/38,513) of male cancer diagnoses. Among women Veterans, breast
cancer was the most commonly diagnosed, accounting for about 30% (292/989) of female
cancers. For both sexes, cancers of the lung and bronchus, and colon and rectum, occur
second and third most frequently, respectively. Urinary bladder is fourth in ranking for men
both nationally and within VA (1,397/38,513), comprising 4% of VA male cancer
diagnoses. For women in the VA, the fourth ranked cancer is corpus uteri (49/989),
accounting for 5% of female cancers.
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Racial Differences in Incidence
Table 3 provides a tabulation of incident cases by cancer site and racial group. Moderate
differences between White and Black Veterans are apparent, such as for lung and bronchus
(19.7% vs. 15.5%) and melanoma (4.2% vs. 0.1%). The most striking difference is in
prostate cancer, which accounted for 28.9% of cancers in White Veterans but 42.7% of
cancers in Black Veterans.
Age Distribution
The median age of Veterans enrolled in VA is approximately 57 years16, compared to the
median age of the general population of approximately 38 years.18 However, the median age
at diagnosis for VA cancers in both sexes in 2007 was 67 years, exactly the same as the
median age at diagnosis for all SEER cancer sites.19 The most cancers occurred in Veterans
aged 55–64 years, accounting for approximately 37% of cancer diagnoses (Table 4). Those
aged 65–74 years were the second most frequently diagnosed group, with 28% of cancer
diagnoses. These age categories also had the highest number of incident cases after age-
adjustment. After adjusting the age structure of the VA population to that of the 2000 U.S.
Standard Population, we estimated that the age-adjusted cancer incidence is 426 cases per
100,000 person-years.
The median age at diagnosis differed between men and women. Among male Veterans with
cancer, the median age at diagnosis was 66 years, while it was 58 among females. Age at
diagnosis in women in VA is nearly 10 years younger than among all women with cancer.
National SEER estimates from 2003–2007 depict an overall median age at diagnosis of 65
years for women diagnosed with any type of cancer.19 In addition, median age at diagnosis
within sexes has remained relatively consistent over time within the VA cancer patient
population. For women, the median age at diagnosis has ranged from 58–61 years over the
span of 2000–2007. Similarly, men’s median age at diagnosis has been approximately 67
years over the same seven-year span. The median age at diagnosis varied slightly according
to anatomic site. For prostate cancer, the median age at diagnosis was 66 years. This is
similar to the SEER national estimate, which is 67 years.19 For VA colorectal cancer
patients, median age at diagnosis was 68 years, identical to the SEER estimate. However,
VA lung cancer patients are slightly younger at diagnosis than those in the U.S. as a whole.
Within VA, the median age at lung cancer diagnosis is 68 years; the SEER median age at
diagnosis for men is 70 years.19
Geographic Distribution
The geographic distribution of cancer patients in VA generally mirrors the geographic
distribution of VA users. Among Veterans enrolled in VA, more live in the South,
approximately 41%, compared to other regions. The Midwest and West each contain about
20% of the VA population. Slightly fewer (17%) live in the Northeast. The South has
approximately 42% (16,738/39,505), Midwest 22% (8,869/39,505), West 21%
(8,295/39,505), and Northeast 14% (5,603/39,505) of VA cancer patients.
Distribution of Stage at Diagnosis
Stage at diagnosis is an important predictor of prognosis and five-year survival rates.4 Stage
at diagnosis was examined for the three most commonly occurring cancer sites: lung and
bronchus, colon and rectum, and prostate. The distribution of stage at diagnosis in VA
differs from that in the general population for these cancers.
In 2007, approximately 23% (1,699/7,437) of lung cancer diagnoses made in VA were
localized. In contrast, only 15% of the SEER lung cancer population was diagnosed with
localized disease.19 Similarly, slightly under 46% of lung cancers (3,431/7,437) in VA were
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metastatic at time of diagnosis, compared with 56% in the broader population.19 Colon and
rectal cancer rates follow a similar pattern of earlier stage at diagnosis within VA. In VA,
approximately 42% (1,441/2,384) of colorectal cancers are localized at diagnosis, compared
with about 39% in the SEER population. The rate of diagnosis of metastatic colorectal
cancer is similar with about 18% (614/2,384) in VA and 19% in the SEER populations.19
Likewise, prostate cancers are diagnosed earlier among Veterans. Approximately 89%
(11,117/12,544) of VA prostate cancers are localized when diagnosed, compared with 80%
in the broader population. Rates of metastatic prostate cancer diagnosis are the same in VA
and outside at approximately 4%.19
Changes in the Number of VA Incident Cancers
As the number of VA patients has grown, there has been a commensurate increase in the
number of incident cancer cases in the VA from 2001 to 2007. Breast and lung cancer
incidence remained stable. However, liver and prostate cancers are on an upward trend.
Incident prostate cancer cases rose from 11,603 to 12,544 per year over this six-year span –
an increase of 941 cases, representing an absolute 2% increase in prostate cancer’s fraction
of overall VA cancer cases. During this timeframe, the number of new liver cancer cases
increased from 570 to 1,057 cases – an increase of 487 cases, which represents a near-
doubling of crude frequency of liver cancer over six years. Conversely, colorectal cancer
experienced a slight decline in both incidence and rate. There was a decrease of 351
colorectal cancer patients between 2001 (3,865) and 2007 (3,446). This equates to a 1.2%
decrease in colorectal cancer’s fraction of total cancer cases. Given the small number of
incident cases, breast cancer remains a small fraction of cancers in VA (0.9%); this fraction
has remained constant from 2001 to 2007.
DISCUSSION
Data from the VA Central Cancer Registry (VACCR) in 2007 suggest that cancer incidence
in the VA is similar to that which is seen in the general male U.S. cancer patient population.
Over 45,000 new cases of cancer were diagnosed in VA, approximately 40,000 of which
were invasive. It is estimated that VA cares for 175,000 Veteran cancer patients annually,
with over 3% of all U.S. cancer diagnoses made in VA each year.4
The Veteran Affairs patient population is a unique subset of the American population, with a
distinct demographic distribution.6 Following the historical composition of the U.S. military,
VA serves a predominately male population. However, the composition of the Nation’s
military is evolving – transforming the future Veteran population. Women comprise a small,
but increasing portion of VA patients. Of those who have served in the military since 1990,
approximately 15% are women.22 In addition, Veteran patients are older than the general US
population. Most healthcare systems have a more expansive distribution of age groups;
however, the requirement for prior military service limits the number of VA patients under
the age of 20. Most are considerably older – the median age of Veterans is approximately 57
years compared to the median age of the general population of approximately 38 years.18 As
the sex and age distribution of the overall Veteran population shifts, the cancer composition
will also change. These demographic differences between Veterans and the overall U.S.
population result in differences in the cancers identified and treated in VA.
Moreover, when compared with nationally published cancer statistics, the most commonly
diagnosed cancers for Veterans are similar to those of the male United States population.3, 4
However, the frequency of these cancers as a fraction of all cancers in VA varies somewhat
from national percentages. For example, approximately 25% of cancer diagnoses in men
nationally are prostate,3, 4 while within VA, prostate cancer accounts for approximately 33%
of male cancer diagnoses. These differences may be a reflection of the older age of the VA
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population relative to the general U.S. population.6 Similarly, younger age and earlier stage
at diagnosis have been associated with better prognosis and increased survival rates,4 but
patients qualifying for and using VA healthcare tend to be older. As a result of this changing
demographic, interpretation of age and sex differences is complex. The overall age of female
Veterans treated within VA is younger than that of their male counterparts. This is due to the
changing sex composition of military service members.20,21 As a result, the difference in
median age at diagnosis between men and women may reflect the fact that female VA
patients tend to be younger than male VA patients.
Several studies have noted racial variations in cancer incidence and treatment.4 The U.S.
Census Bureau (which surveys all Veterans, not just those using the VA healthcare system)
estimates that 83% of Veterans are White and under 10% of Veterans are African-
American.16 There is evidence that users of the VA healthcare system are more likely to be
African American, are less likely to be employed, and likely has a lower annual income.17
The observed racial distribution of cancer in VA (78.5% among White and 19% among
Black) reflects a similar burden of illness among Black Veterans.
We found that patients in VA are diagnosed with commonly occurring cancers at earlier
stages, relative to the general population. This finding is consistent with evidence from the
Government Performance Review Act Report on Oncology (2010).23 Intensive screening
directives and an electronic clinical reminder system may be responsible for earlier
detection. However, VA has no screening program for lung cancer, which had the largest
shift toward earlier stage at diagnosis in VA relative to the US population. VA patients
diagnosed with lung cancer have more frequent and more severe lung disease,23 which may
prompt more frequent diagnostic evaluation that may incidentally result in diagnosis of
asymptomatic lung cancer.
This analysis provides anecdotal evidence of VACCR’s utility as an epidemiological
tracking and research tool. This finding has important implications. VACCR has a myriad of
potential future uses. VACCR data could be used to assemble and report measurements of
incident cancers among Veterans; to provide information on changes over time in extent of
disease at diagnosis and treatment; to promote and conduct studies designed to identify
factors relating to cancer etiology, prevention, and control; to respond to requests from
individuals and organizations in the Department of Veterans Affairs for cancer data and
analysis; and to provide data and expertise for cancer research activities and educational
opportunities. These possible uses of VACCR could aid decision-making for resource
allocation and to provide a data source for research.
VACCR data have served an integral role in informing numerous VA quality improvement
and research initiatives. Specifically, VACCR data have been used as a basis for cancer case
identification and patient tracking for a number of studies examining colorectal cancer
screening, diagnosis, receipt of guideline-concordant cancer care, and timeliness of
treatment.10, 24–26 VACCR data have also been examined to assess possible changes in the
composition of VA cancer cases and related diseases over time.24, 25 Data from the VACCR
have also been utilized to make comparisons between VA cancer care and care delivered in
the private sector. It has been determined that cancer care for older Americans is generally
equivalent in both settings.23 Furthermore, data have been used to identify cancer patients
that may be eligible for research initiatives or may be experiencing barriers to cancer care.27
Limitations
Despite the utility of VACCR data, this analysis has important limitations. Previous studies
have indicated that that VACCR captures an estimated 87% to nearly 90% or better of
cancer patients treated by the VA.10, 20 Like most registries, VACCR is tasked with
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systematic collection of data about cancer incidence. By design, VACCR does not currently
contain timely mortality data; for example, only 7% of patients diagnosed with lung cancer
in 2001 are recorded as deceased in VACCR. This makes calculating survival rates and
outcomes based solely on VACCR data difficult. A positive difference between the VA
cancer registry and other cancer registries is that VA has access to system-wide integrated
electronic medical record and supporting administrative data. Furthermore, the quality of
VACCR is currently unknown, but there is an ongoing validation project comparing
VACCR data with manually abstracted data from the electronic medical record for a sample
of lung cancer cases. VACCR data can be supplemented with administrative vital status
information. These resources also better equip VA to accurately measure its registry capture
rate, whereas other registries must rely upon population predictions.
A second limitation of this analysis is that the estimated annual incidence rates should not be
generalized to all Veterans in the United States. Veterans have a choice in where they
receive their healthcare. Patients may receive all or part of their care in the private sector.
Some Veterans may begin using VA healthcare services upon receiving a diagnosis of
cancer elsewhere. This leads to healthcare system overlap. For example, patients may be
counted both in a SEER registry and in the VACCR.28 This could result in duplication bias.
The SEER summary data is a historical data comparison, therefore caution should be
exercised in interpreting this comparison.
It should be noted that patients using the VA tend to be older, sicker, and of lower
socioeconomic status than the overall U.S. and Veteran populations as a whole.29 As a
result, estimates presented in this report apply only to patients receiving care in the VA
healthcare system, not all Veterans in the United States. Furthermore, these underlying
differences in the VA patient population and the general U.S. result in limited
generalizability of study findings to a broader national context.
Third, the age-adjusted incidence rates should be interpreted with caution. The “population”
of VA patients is dependent on definitions of who uses the healthcare system. Population
figures were obtained from the VA Office of Policy and Planning (OPP). In addition,
information was not available to subtract individuals with prevalent cancer from the VA
population denominator, which could lead to an under-estimate of incidence rate. However,
this may be offset by the fact that the VA cancer registry does not capture all incident cases.
As a result, the numbers should be interpreted as the best available approximation of the
age-adjusted incidence rate available, but not exact numbers.
Similarly, we were unable to obtain information about the underlying racial distribution of
patients using the VA healthcare system. As a result, we were unable to produce race-
adjusted statistics. Future analyses would be strengthened by adjusting for both age and race.
CONCLUSION
VA Central Cancer Registry data indicate that incident cancers in VA in 2007 approximately
mirrored those observed among U.S. men. Furthermore, data from the VA Central Cancer
Registry are pivotal to provide accurate estimates of VA cancer incidence. This information
can be used to plan efforts to improve quality of cancer care and access to services. These
registry data indicate that incident cancers in VA in 2007 approximately mirrored those
observed among U.S. men.
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Table 1
Number of Cases Reported Annually to VA Central Cancer Registry, 1995–2007.a
Year Number of Reporting Facilitiesb Number of Cases Average Number of Cases Per Facility
1995 99 31,291 316
1996 100 31,173 312
1997 104 31,111 299
1998 105 33,440 318
1999 110 34,877 317
2000 112 36,941 330
2001 114 38,835 341
2002 115 39,725 345
2003 116 38,802 335
2004 117 39,621 339
2005 121 38,788 321
2006 123 40,085 326
2007 129 39,505 306
Total -- 474,194 --
a
Cases with a SEER summary stage of 0 have been excluded.
b
A facility is defined as a VA medical center (primary, secondary, or tertiary) that has the capacity to diagnosis and treat cancer. The number of
reporting facilities for each year and definition of “facility” were provided by the National Program Director of VACCR.
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Table 2
Incident Cancer Cases by Sex in Veteran Affairs Patients, 2007.a
Incident Cases, 2007
p-valuec
All Sexes n (% total
cancers) Male n (% male cancers)
Female n (% female
cancers)
All sites 39505 38513 989
Head & neck 1712 (4.3%) 1689 (4.4%) 23 (2.3%) --
 Tongue 452 (1.1%) 443 (1.2%) 9 (0.9%)
 Lip 101 (0.3%) 101 (0.3%) 0 (0%)
 Mouth 746 (1.9%) 739 (1.9%) 7 (0.7%)
 Pharynx 357 (0.9%) 350 (0.9%) 7 (0.7%)
 Nasal cavity & sinuses 56 (0.1%) 56 (0.1%) 0 (0%)
Digestive system 6965 (17.6%) 6827 (17.7%) 137 (13.9%) 0.0016
 Esophagus 804 (2.0%) 798 (2.1%) 6 (0.6%)
 Stomach 548 (1.4%) 543 (1.4%) 5 (0.5%)
 Small intestine 127 (0.3%) 124 (0.3%) 3 (0.3%)
 Colon 2384 (6.0%) 2329 (6.1%) 55 (5.6%)
 Rectumb 1037 (2.6%) 1015 (2.6%) 21 (2.1%)
 Anus 137 (0.4%) 122 (0.3%) 15 (1.5%)
 Liver & intrahepatic bile duct 1054 (2.7%) 1039 (2.7%) 15 (1.5%)
 Gallbladder 18 (<0.1%) 16 (<0.1%) 2 (0.2%)
 Pancreas 727 (1.8%) 713 (1.9%) 14 (1.4%)
 Other digestive organs 129 (0.3%) 128 (0.3%) 1 (0.1%)
Respiratory system 8254 (20.9%) 8090 (21.0%) 164 (16.6%) 0.0007
 Larynx 807 (2.0%) 800 (2.1%) 7 (0.7%)
 Lung & bronchus 7437 (18.8%) 7280 (18.9%) 157 (15.9%)
 Other respiratory organs 10 (<0.1%) 10 (<0.1%) 0 (0%)
Bones & joints 25 (<0.1%) 23 (<0.1%) 2 (0.2%) --
Bone Marrow 484 (1.2%) 471 (1.2%) 13 (1.3%) --
Soft tissue (including heart) 175 (0.4%) 168 (0.4%) 7 (0.7%) --
Melanoma 1327 (3.4%) 1289 (3.4%) 38 (3.8%) 0.39
Breast 358 (0.9%) 66 (0.2%) 292 (29.5%) --
Genital system 12812 (32.4%) 12701 (33.0%) 110 (11.1%) --
 Uterine cervix 32 (<0.1%) N/A 32 (3.2%)
 Uterine corpus 49 (0.1%) N/A 49 (5.0%)
 Ovary 15 (<0.1%) N/A 15 (1.5%)
 Vulva 9 (<0.1%) N/A 9 (0.9%)
 Vagina & other genital female 5 (<0.1%) N/A 5 (0.5%)
 Prostateb 12544 (31.8%) 12543 (32.6%) N/A
 Testis 77 (0.2%) 77 (0.2%) N/A
 Penis & other genital male 81 (0.2%) 81 (0.2%) N/A
Urinary system 2804 (7.1%) 2756 (7.2%) 48 (4.9%) 0.0054
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Incident Cases, 2007
p-valuec
All Sexes n (% total
cancers) Male n (% male cancers)
Female n (% female
cancers)
 Urinary bladder 1417 (3.6%) 1397 (3.6%) 20 (2.0%)
 Kidney & renal pelvis 1307 (3.3%) 1279 (3.3%) 28 (2.8%)
 Ureter & other urinary organs 80 (0.2%) 80 (0.2%) 0 (0%)
Eye & Orbit 24 (0.1%) 24 (0.1%) 0 (0%) --
Central nervous system 370 (0.9%) 350 (0.9%) 20 (2.0%) --
 Brain 264 (0.7%) 257 (0.7%) 7 (0.7%)
 Other central nervous system 106 (0.3%) 93 (0.2%) 13 (1.3%)
Endocrine system 458 (1.2%) 408 (1.1%) 50 (5.1%) < 0.0001
 Thyroid 373 (0.9%) 329 (0.9%) 44 (4.5%)
 Other endocrine 85 (0.2%) 79 (0.2%) 6 (0.6%)
Lymphoma 1244 (3.2%) 1207 (3.1%) 37 (3.7%) 0.28
 Hodgkin lymphoma 92 (0.2%) 89 (0.2%) 3 (0.3%)
 Non-Hodgkin lymphoma 1152 (2.9%) 1118 (2.9%) 34 (3.4%)
Myeloma 449 (1.1%) 441 (1.2%) 8 (0.8%) --
Leukemia 901 (2.3%) 883 (2.3%) 18 (1.8%) --
Other & unspecified primary sitesb 1143 (2.9%) 1120 (2.9%) 22 (2.2%) --
a
Cases with a SEER summary stage of 0 have been excluded.
b
Columns may not sum to All Sexes due to presence of Other/Not stated sex.
c
p-values are presented for male-female comparison within organ systems with a minimum of 25 cases in each category.
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Table 3
Incident Cancers by Site and Race in Veteran Affairs Patients, 2007.a
White Black Other
p-valuebN=31,010 N=7,523 N=972
Head & neck 1408 (4.5%) 260 (3.5%) 44 (4.5%) < 0.0001
 Tongue 392 (1.3%) 51 (0.7%) 9 (0.9%)
 Lip 100 (0.3%) 0 (0%) 1 (0.1%)
 Mouth 613 (2.0%) 114 (1.5%) 19 (2.0%)
 Pharynx 258 (0.8%) 88 (1.2%) 11 (1.1%)
 Nasal cavity & sinuses 45 (0.2%) 7 (<0.1%) 4 (0.4%)
Digestive system 5381 (17.4%) 1418 (18.9%) 166 (17.1%) 0.0023
 Esophagus 647 (2.1%) 140 (1.9%) 17 (1.8%)
 Stomach 366 (1.2%) 157 (2.1%) 25 (2.6%)
 Small intestine 95 (0.3%) 30 (0.4%) 2 (0.2%)
 Colon 1878 (6.1%) 459 (6.1%) 47 (4.8%)
 Rectum 832 (2.7%) 183 (2.4%) 22 (2.3%)
 Anus 106 (0.3%) 28 (0.4%) 3 (0.3%)
 Liver & intrahepatic bile duct 766 (2.5%) 260 (3.5%) 28 (2.9%)
 Gallbladder 16 (<0.1%) 2 (<0.1%) 0 (0%)
 Pancreas 574 (1.9%) 136 (1.8%) 17 (1.8%)
 Other digestive organs 101 (0.3%) 23 (0.3%) 5 (0.5%)
Respiratory system 6763 (21.8%) 1327 (17.6%) 164 (16.9%) < 0.0001
 Larynx 635 (2.1%) 158 (2.1%) 14 (1.4%)
 Lung & bronchus 6118 (19.7%) 1169 (15.5%) 150 (15.4%)
 Other respiratory organs 10 (<0.1%) 0 (0%) 0 (0%)
Bones & joints 24 (<0.1%) 1 (<0.1%) 0 (0%) --
Bone Marrow 414 (1.3%) 65 (0.9%) 5 (0.5%) --
Soft tissue (including heart) 136 (0.4%) 33 (0.4%) 6 (0.6%) --
Melanoma 1301 (4.2%) 10 (0.1%) 16 (1.7%) --
Breast 274 (0.9%) 74 (1.0%) 10 (1.0%) --
Genital system 9179 (29.6%) 3248 (43.2%) 385 (39.6%) < 0.0001
 Uterine cervix 16 (<0.1%) 11 (0.1%) 5 (0.5%)
 Uterine corpus 42 (0.1%) 6 (<0.1%) 1 (0.1%)
 Ovary 14 (<0.1%) 1 (<0.1%) 0 (0%)
 Vulva 6 (<0.1%) 2 (<0.1%) 1 (0.1%)
 Vagina & other genital female 5 (<0.1%) 0 (0%) 0 (0%)
 Prostate 8963 (28.9%) 3210 (42.7%) 371 (38.2%)
 Testis 65 (0.2%) 8 (0.1%) 4 (0.4%)
 Penis & other genital male 68 (0.2%) 10 (0.1%) 3 (0.3%)
Urinary system 2340 (7.6%) 404 (5.4%) 60 (6.2%) < 0.0001
 Urinary bladder 1247 (4.0%) 134 (1.8%) 36 (3.7%)
 Kidney & renal pelvis 1024 (3.3%) 260 (3.5%) 23 (2.4%)










Zullig et al. Page 15
White Black Other
p-valuebN=31,010 N=7,523 N=972
 Ureter & other urinary organs 69 (0.2%) 10 (0.1%) 1 (0.1%)
Eye & Orbit 23 (<0.1%) 1 (<0.01%) 0 (0%) --
Central nervous system 318 (1.0%) 45 (0.6%) 7 (0.7%) --
 Brain 236 (0.8%) 23 (0.3%) 5 (0.5%)
 Other central nervous system 82 (0.3%) 22 (0.3%) 2 (0.2%)
Endocrine system 359 (1.2%) 71 (0.9%) 28 (2.9%) 0.11
 Thyroid 303 (1.0%) 46 (0.6%) 24 (2.5%)
 Other endocrine 56 (0.2%) 25 (0.3%) 4 (0.4%)
Lymphoma 1057 (3.4%) 167 (2.2%) 20 (2.1%) --
 Hodgkin lymphoma 70 (0.2%) 21 (0.3%) 1 (0.1%)
 Non-Hodgkin lymphoma 987 (3.2%) 146 (1.9%) 19 (2%)
Myeloma 304 (1.0%) 131 (1.7%) 14 (1.4%) --
Leukemia 783 (2.5%) 94 (1.3%) 24 (2.5%) --
Other & unspecified primary sites 946 (3.1%) 174 (2.3%) 23 (2.4%) --
a
Cases with a SEER summary stage of 0 have been excluded.
b
p-values are presented for black-white comparison within organ systems with a minimum of 25 cases in each category.
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